Search research articles
Contact Us
Filters
Showing results (121-130 of 139) with videos related to
Page
of 14
Sort By:
Psychopharmacology Bulletin
|
October 1, 1980
Human memory and the effects of physostigmine and choline chloride [proceedings]
K L Davis, R C Mohs, B M Davis, et al.
The American Journal of Psychiatry
|
January 1, 1985
Oral physostigmine treatment of patients with Alzheimer's disease
R C Mohs, B M Davis, C A Johns, et al.
Oncogene
|
May 9, 2007
p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation
E V Broude, M E Swift, C Vivo, et al.
Biological Psychiatry
|
July 15, 1992
Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation
G K Tsuboyama, S S Gabriel, B M Davis, et al.
Science (New York, N.Y.)
|
March 29, 1985
Plasma homovanillic acid concentration and the severity of schizophrenic illness
K L Davis, M Davidson, R C Mohs, et al.
The American Journal of Psychiatry
|
July 1, 1984
Age and the dexamethasone suppression test in depression
K L Davis, B M Davis, A A Mathé, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 11, 2001
Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells
B M Davis, L P Encell, S P Zielske, et al.
Archives of General Psychiatry
|
May 1, 1984
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses
M I Levy, B M Davis, R C Mohs, et al.
Mitochondrion
|
May 21, 2019
Corrigendum to "Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension" [Mitochondrion 36 (2017) 114-123]
B M Davis, K Tian, M Pahlitzsch, et al.
Archives of General Psychiatry
|
March 1, 1985
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems
B M Davis, K L Davis, R C Mohs, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 139) with videos related to
Sort By:
Page
of 14
Psychopharmacology Bulletin
|
October 1, 1980
Human memory and the effects of physostigmine and choline chloride [proceedings]
K L Davis, R C Mohs, B M Davis, et al.
The American Journal of Psychiatry
|
January 1, 1985
Oral physostigmine treatment of patients with Alzheimer's disease
R C Mohs, B M Davis, C A Johns, et al.
Oncogene
|
May 9, 2007
p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation
E V Broude, M E Swift, C Vivo, et al.
Biological Psychiatry
|
July 15, 1992
Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation
G K Tsuboyama, S S Gabriel, B M Davis, et al.
Science (New York, N.Y.)
|
March 29, 1985
Plasma homovanillic acid concentration and the severity of schizophrenic illness
K L Davis, M Davidson, R C Mohs, et al.
The American Journal of Psychiatry
|
July 1, 1984
Age and the dexamethasone suppression test in depression
K L Davis, B M Davis, A A Mathé, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 11, 2001
Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells
B M Davis, L P Encell, S P Zielske, et al.
Archives of General Psychiatry
|
May 1, 1984
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses
M I Levy, B M Davis, R C Mohs, et al.
Mitochondrion
|
May 21, 2019
Corrigendum to "Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension" [Mitochondrion 36 (2017) 114-123]
B M Davis, K Tian, M Pahlitzsch, et al.
Archives of General Psychiatry
|
March 1, 1985
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems
B M Davis, K L Davis, R C Mohs, et al.
Page
of 14